Cargando…

Adherence to treatment regimen and bleeding rates in a prospective cohort of youth and young adults on low-dose daily prophylaxis for severe hemophilia A

BACKGROUND: When availability and/or affordability of anti-hemophilic factor concentrates are limited, optimal prophylaxis regimens in severe hemophilia A (HA) remain to be determined. In selected situations, low-dose daily prophylaxis (LDDP) may be an effective and economical option. The goal of ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mizrahi, Terry, St-Louis, Jean, Young, Nancy L., Ménard, Francine, Zourikian, Nichan, Dubé, Evemie, Rivard, Georges E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5101823/ https://www.ncbi.nlm.nih.gov/pubmed/27833753 http://dx.doi.org/10.1186/s12878-016-0067-3

Ejemplares similares

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
por: Dover, Saunya, et al.
Publicado: (2020)

Generic and disease-specific quality of life among youth and young men with Hemophilia in Canada
por: St-Louis, J., et al.
Publicado: (2016)

Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis
por: Garcia, Jessica, et al.
Publicado: (2023)

The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study
por: St‐Louis, Jean, et al.
Publicado: (2022)

Iranian Low-dose Escalating Prophylaxis Regimen in Children with Severe Hemophilia A and B
por: Eshghi, Peyman, et al.
Publicado: (2017)

A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management
por: VALENTINO, L A, et al.
Publicado: (2012)

The Perspectives of Adolescents and Young Adults on Adherence to Prophylaxis in Hemophilia: A Qualitative Study
por: Hoefnagels, JW, et al.
Publicado: (2020)

Adherence to hemophilia patients with prophylaxis: Veritas-Pro and psychometric properties adapted to Turkish
por: Mehrekula Demirci, Zuhal, et al.
Publicado: (2023)

Efficacy of Nuwiq(®) (Simoctocog Alfa) in Patients with Hemophilia A Who Changed and Adhered to a Pharmacokinetic-Guided Prophylaxis Regimen in the NuPreviq Study
por: Pasi, K John
Publicado: (2021)

Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
por: Jonsson, Fredrik, et al.
Publicado: (2021)

Optimization of prophylaxis for hemophilia A
por: Herbert, Robert D., et al.
Publicado: (2018)

Magnetic resonance imaging in boys with severe hemophilia A: Serial and end‐of‐study findings from the Canadian Hemophilia Primary Prophylaxis Study
por: Stimec, Jennifer, et al.
Publicado: (2021)

Validation of the Brazilian version of the VERITAS-Pro scale to assess adherence to prophylactic regimens in hemophilia
por: Ferreira, Adriana Aparecida, et al.
Publicado: (2018)

Treatment adherence in hemophilia
por: Thornburg, Courtney D, et al.
Publicado: (2017)

Correction: Optimization of prophylaxis for hemophilia A
por: Herbert, Robert D., et al.
Publicado: (2018)

Adherence to prophylaxis and bleeding outcome: A multicenter Nigerian study
por: Nwagha, Theresa Ukamaka, et al.
Publicado: (2023)

Validation of the Spanish Version of the VERITAS-PRN Scale to Assess Adherence to on Demand Regimens in Patients with Hemophilia
por: Torres-Ortuño, Ana, et al.
Publicado: (2021)

Among once-daily regimens, single tablet regimens (STRs) are associated with better adherence
por: Murri, R, et al.
Publicado: (2012)

Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A
por: Rossbach, Hans-Christoph
Publicado: (2010)

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model
por: Tiede, Andreas, et al.
Publicado: (2020)

Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Hemophilia A in India
por: Choraria, Nirmalkumar, et al.
Publicado: (2022)

Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya
por: Mugo, Peter Mwangi, et al.
Publicado: (2014)

Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions
por: Jackson, Shannon C, et al.
Publicado: (2015)

Acquired Hemophilia A with Gastrointestinal Bleeding
por: Park, Narae, et al.
Publicado: (2020)

The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022)

Predictors of Re-Initiation of Daily Oral Preexposure Prophylaxis Regimen After Discontinuation
por: Xavier Hall, Casey D., et al.
Publicado: (2022)

Real pandemic world results of pharmacokinetic-tailored personalized prophylaxis of bleeds in Polish children and adolescents with severe hemophilia A
por: Urasiński, Tomasz, et al.
Publicado: (2023)

Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India
por: Choraria, Nirmalkumar, et al.
Publicado: (2022)

Prevention and Management of Bleeding Episodes in Children with Hemophilia
por: Ljung, Rolf C. R.
Publicado: (2018)

An Unusual Case of Bleeding: Acquired Hemophilia A
por: Jahangiri, Omeed S, et al.
Publicado: (2023)

Hematuria in aging men with hemophilia: Association with factor prophylaxis
por: Qvigstad, Christian, et al.
Publicado: (2020)

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
por: Shapiro, Amy D., et al.
Publicado: (2022)

Antithrombin inhibition using nanobodies to correct bleeding in hemophilia
por: O'Sullivan, Jamie M, et al.
Publicado: (2020)

Immunosuppression Therapy in Acquired Hemophilia A: Pursuing an Optimal Regimen
por: Teixeira Passos, Dúlio, et al.
Publicado: (2021)

Wheelchair service provision education in Canadian occupational therapy programs
por: Giesbrecht, Ed M., et al.
Publicado: (2022)

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea
por: Moon, Byung Suk, et al.
Publicado: (2013)

Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study
por: Wu, Runhui, et al.
Publicado: (2021)

Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center
por: Cohen, Omri, et al.
Publicado: (2023)

Prevention and Management of Bleeding Episodes in Patients with Acquired Hemophilia A
por: Knöbl, Paul
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mvtcfkgkteuc5h33bnhs7kpa1b